Hope rises again for a drug to slow Alzheimer’s disease

Hopes are rising again for a drug to alter the course of Alzheimer's disease after decades of failures. An experimental therapy slowed mental decline by 30 percent in patients who got the highest dose in a mid-stage study, and it removed much of the sticky plaque gumming up their brains, the drug's makers said Wednesday.

The results have been highly anticipated and have sent the stock of the two companies involved soaring in recent weeks.

The drug from Eisai and Biogen did not meet its main goal in a study of 856 participants, so overall, it was considered a flop. But company officials said that 161 people who got the highest dose every two weeks for 18 months did significantly better than 245 people who were given a dummy treatment.

There are lots of caveats about the work, which was led by company scientists rather than academic researchers and not reviewed by outside experts. The study also was too small to be definitive and the results need to be confirmed with more work, dementia experts said. But they welcomed any glimmer of success after multiple failures.

Comments

Popular posts from this blog

There is mounting evidence that herpes leads to Alzheimers Disease

Alzheimers 2018

15 Things That Slow Down Alzheimer’s Disease